The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma
MET, a receptor tyrosine kinase proto-oncogene and the specific receptor for hepatocyte growth factor (HGF), plays a critical role in the initiation and progression of osteosarcoma (OS) through sustained pathway activation. Aberrant activation of MET has been shown to trigger multiple downstream sig...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/or.2025.1615111/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850219824518529024 |
|---|---|
| author | Qilong Su Jingyu Hou Xinhui Du Fan Zhang Panhong Zhang Bangmin Wang Weitao Yao |
| author_facet | Qilong Su Jingyu Hou Xinhui Du Fan Zhang Panhong Zhang Bangmin Wang Weitao Yao |
| author_sort | Qilong Su |
| collection | DOAJ |
| description | MET, a receptor tyrosine kinase proto-oncogene and the specific receptor for hepatocyte growth factor (HGF), plays a critical role in the initiation and progression of osteosarcoma (OS) through sustained pathway activation. Aberrant activation of MET has been shown to trigger multiple downstream signalling pathways, including RAS-ERK, PI3K-AKT, and STAT3, which are essential for OS cell proliferation, invasion, differentiation, and drug resistance. In recent years, significant progress has been made in the development of small-molecule inhibitors and specific antibodies targeting MET for OS therapy. The use of combination therapy as a treatment strategy involves the use of MET inhibitors in conjunction with chemotherapy, immunotherapy, and other targeted therapies. This approach has the potential to overcome resistance and improve therapeutic efficacy. This review summarises the mechanisms of MET signalling in OS, with a focus on the progress of MET-targeted therapies and their combination with other therapeutic strategies. The study provides valuable insights into future research directions, offering novel perspectives on the role of MET as a therapeutic target in OS. |
| format | Article |
| id | doaj-art-401865effcb4457ba740d84ed5c93d73 |
| institution | OA Journals |
| issn | 1970-5557 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj-art-401865effcb4457ba740d84ed5c93d732025-08-20T02:07:16ZengFrontiers Media S.A.Oncology Reviews1970-55572025-06-011910.3389/or.2025.16151111615111The role and research progress of the MET signalling pathway in targeted therapy for osteosarcomaQilong SuJingyu HouXinhui DuFan ZhangPanhong ZhangBangmin WangWeitao YaoMET, a receptor tyrosine kinase proto-oncogene and the specific receptor for hepatocyte growth factor (HGF), plays a critical role in the initiation and progression of osteosarcoma (OS) through sustained pathway activation. Aberrant activation of MET has been shown to trigger multiple downstream signalling pathways, including RAS-ERK, PI3K-AKT, and STAT3, which are essential for OS cell proliferation, invasion, differentiation, and drug resistance. In recent years, significant progress has been made in the development of small-molecule inhibitors and specific antibodies targeting MET for OS therapy. The use of combination therapy as a treatment strategy involves the use of MET inhibitors in conjunction with chemotherapy, immunotherapy, and other targeted therapies. This approach has the potential to overcome resistance and improve therapeutic efficacy. This review summarises the mechanisms of MET signalling in OS, with a focus on the progress of MET-targeted therapies and their combination with other therapeutic strategies. The study provides valuable insights into future research directions, offering novel perspectives on the role of MET as a therapeutic target in OS.https://www.frontiersin.org/articles/10.3389/or.2025.1615111/fullosteosarcomaMET signalling pathwaytargeted therapysmall molecule inhibitorsspecific antibodycombination therapy |
| spellingShingle | Qilong Su Jingyu Hou Xinhui Du Fan Zhang Panhong Zhang Bangmin Wang Weitao Yao The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma Oncology Reviews osteosarcoma MET signalling pathway targeted therapy small molecule inhibitors specific antibody combination therapy |
| title | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma |
| title_full | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma |
| title_fullStr | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma |
| title_full_unstemmed | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma |
| title_short | The role and research progress of the MET signalling pathway in targeted therapy for osteosarcoma |
| title_sort | role and research progress of the met signalling pathway in targeted therapy for osteosarcoma |
| topic | osteosarcoma MET signalling pathway targeted therapy small molecule inhibitors specific antibody combination therapy |
| url | https://www.frontiersin.org/articles/10.3389/or.2025.1615111/full |
| work_keys_str_mv | AT qilongsu theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT jingyuhou theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT xinhuidu theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT fanzhang theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT panhongzhang theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT bangminwang theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT weitaoyao theroleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT qilongsu roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT jingyuhou roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT xinhuidu roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT fanzhang roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT panhongzhang roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT bangminwang roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma AT weitaoyao roleandresearchprogressofthemetsignallingpathwayintargetedtherapyforosteosarcoma |